12 not yet recruiting, 4 recruiting, 1 completed. 9 Phase 2, 3 Phase 1, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Not yet recruiting 5, Recruiting 4 |
| Phase 1 | 3 | Not yet recruiting 2, Recruiting 1 |
| Phase 3 | 3 | Not yet recruiting 2, Recruiting 1 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow Fallopian Tube Cancers: new trials by email Literature Review of Fallopian Tube Cancers trials Research Report on Fallopian Tube Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer Upfront cytoreductive surgery, Interval debulking surgery, Platinum-based chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 534 | 2026-12-31 | 2026-11-12 |
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 53 | 2026-10-22 | 2026-10-01 |
| Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | University of Colorado, Denver | 40 | 2026-09-01 | 2026-09-11 |
| Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer (Arginaid®) Oral Arginine, (R-Gene® 10) IV Arginine, Pembrolizumab - Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Rebecca Arend | 24 | 2026-09-01 | 2026-10-15 |
| Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III | Not yet recruiting | Latin American Cooperative Oncology Group | 320 | 2026-09-01 | 2026-08-25 | |
| Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5) - High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 82 | 2026-07-23 | 2026-11-04 |
| A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα） Mirvetuximab Soravtansine (MIRV) - Ovarian Cancer, Fallopian Tube Cancers | Not yet recruiting | NING LI-GYN | 400 | 2026-07-20 | 2026-07-24 | |
| IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer Sacituzumab govitecan monotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 19 | 2026-07-01 | 2026-06-30 |
| Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer Liposomal Irinotecan - Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-05-30 | 2026-05-18 |
| Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer Benmelstobart in combination with Anlotinib and oral metronomic Cyclophosphamide - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2026-03-30 | 2026-03-24 |
| Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life hand and foot exercises - Peripheral Neuropathy, Cervical Cancer | Not applicable | Not yet recruiting | Taipei Veterans General Hospital, Taiwan | 74 | 2026-01-01 | 2026-01-23 |
| CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin - FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers | Phase 1 / Phase 2 | Recruiting | TORL Biotherapeutics, LLC | 60 | 2025-12-10 | 2026-07-13 |
| Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance Ovarian Cancer, Fallopian Tube Cancers | Not yet recruiting | Tongji Hospital | 600 | 2025-11-27 | 2025-12-08 | |
| PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer PARP inhibitor + Bevacizumab, PARP inhibitor - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 / Phase 3 | Recruiting | N.N. Alexandrov National Cancer Centre | 120 | 2025-07-01 | 2026-03-16 |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine Mirvetuximab Soravtansine - Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer | Phase 2 | Recruiting | AbbVie | 110 | 2025-05-28 | 2026-05-26 |
| JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer JSKN003, Doxorubicin, Paclitaxel - Ovarian Cancer, Primary Peritoneal | Phase 3 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 430 | 2025-01-15 | 2024-12-31 |
| Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel Chemotherapy Standard Chemotherapy (Carboplatin-Paclitaxel) - Ovarian Cancer (OvCa), Fallopian Tube Cancers | Completed | Ankara Etlik City Hospital | 102 | 2024-03-15 | 2025-09-04 |
Fallopian Tube Neoplasms (17) · Ovarian Neoplasms (12) · Carcinoma, Ovarian Epithelial (4) · Endometrial Neoplasms (2) · Dysgeusia (1) · Malnutrition (1) · Peripheral Nervous System Diseases (1) · Sarcopenia (1) · Uterine Cervical Neoplasms (1) · Vaginal Neoplasms (1)
Adnexal Diseases (17) · Fallopian Tube Diseases (17) · Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Genital Diseases (17) · Genital Diseases, Female (17) · Genital Neoplasms, Female (17) · Neoplasms (17) · Neoplasms by Site (17) · Urogenital Diseases (17) · Urogenital Neoplasms (17) · Endocrine Gland Neoplasms (13) · Endocrine System Diseases (13) · Gonadal Disorders (13) · Ovarian Diseases (13)
Bevacizumab (3) · Paclitaxel (3) · Carboplatin (2) · Platinum Compounds (2) · mirvetuximab soravtansine (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Arginine (1) · Atorvastatin (1) · CP protocol (1) · Cyclophosphamide (1) · Dimethoate (1) · Doxorubicin (1) · Poly(ADP-ribose) Polymerase Inhibitors (1) · Standard of Care (1)
Shanghai Gynecologic Oncology Group (2) · AbbVie (1) · Ankara Etlik City Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd (1) · Latin American Cooperative Oncology Group (1) · N.N. Alexandrov National Cancer Centre (1) · NING LI-GYN (1) · Peking University Cancer Hospital & Institute (1) · Rebecca Arend (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · TORL Biotherapeutics, LLC (1) · Taipei Veterans General Hospital, Taiwan (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Tongji Hospital (1)
China (4) · United States (4) · Argentina (1) · Australia (1) · Belarus (1) · Belgium (1) · Brazil (1) · Colombia (1) · France (1) · Mexico (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1)
Galip Can Uyar, MD (1) · Nicole Marjon, MD, PhD (1) · Ning Li, MD (1) · Rebecca C Arend, MD (1)